Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Discovering selective anticancer drugs: succeeding slowly is better than failing fast

13th International Congress on Targeted Anticancer Therapies

Published: 10 Mar 2015

Views: 4669

Rating:

Save

Professor Hilary Calvert - UCL Cancer Institute, London, UK

Professor Calvert talks to ecancertv about molecularly targeted drug discovery, the subject of his TAT Honorary Award Lecture 2015.

Related Videos

EBCC 2024: Addressing inequalities across Europe in access to innovation for...

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr...

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )

Comment: EBCC 2024 highlights

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr...

Comment: EBCC 2024 highlights ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )

Autovaccination with the intratumoral viral mimic poly-ICLC makes a cold tumour...

Dr Sujit Nair - Icahn School of Medicine at Mount Sina, New York, USA

Autovaccination with the intratumoral viral mimic poly-ICLC makes a cold tumour hot in prostate cancer ( Dr Sujit Nair - Icahn School of Medicine at Mount Sina, New York, USA )

Avelumab combined with regorafenib shows improved outcome in solid tumours with...

Prof Antoine Italiano - Institute Bergonié, Bordeaux, France

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures ( Prof Antoine Italiano - Institute Bergonié, Bordeaux, France )

Blood test may identify patients with non-small cell lung cancer subtype who...

Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy ( Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA )

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective...

Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC ( Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows...

Dr Yan Zhang - Sichuan University, Chengdu, China

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC ( Dr Yan Zhang - Sichuan University, Chengdu, China )

More from ecancer